SCHEDULE: Allogene Therapeutics: Dr. Chang's 5.2% Stake

Dr. David D. Chang and affiliated trusts report a combined beneficial ownership of 5.2% in Allogene Therapeutics, Inc. common stock.

Summary

• Dr. David D. Chang, M.D., Ph.D., beneficially owns 12,101,223 shares of Allogene Therapeutics, Inc. common stock, representing 5.2% of the class.
• This ownership includes 6,373,347 shares issuable within 60 days from December 31, 2025, upon the exercise of stock options held by Dr. Chang.
• Dr. Chang's reported ownership also encompasses shares held by the Chang 2006 Family Trust (1,201,108 shares, 0.5%), JEC 2019 Trust (856,044 shares, 0.4%), and RTC 2019 Trust (856,044 shares, 0.4%), for which he serves as co-trustee.
• The percentage of class is calculated based on 224,730,144 shares outstanding as of November 4, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 6, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive due to the continued significant insider ownership by a key co-founder, which can signal confidence, though it provides no new operational or financial performance data.

Positives

• Significant insider ownership by Dr. David D. Chang, a co-founder and former CEO, potentially signaling confidence in the company's long-term prospects.
• Dr. Chang's continued substantial stake, including exercisable options, aligns his interests with those of other shareholders.

Future Outlook

This Schedule 13G filing is a factual report of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future operations or financial performance.

Industry Context

StockSavvy.ai notes that significant insider ownership, such as the 5.2% stake reported by Dr. David D. Chang, a co-founder, is often viewed positively in the biotechnology sector. It can indicate strong conviction from individuals deeply familiar with the company's pipeline and strategic direction, potentially differentiating it from competitors with less insider alignment.

Comparison to Industry Standards

• This filing primarily reports beneficial ownership and does not contain performance metrics for direct comparison to industry standards.
• StockSavvy.ai observes that a 5.2% beneficial ownership by a key individual like a co-founder is a substantial stake, often exceeding typical insider ownership percentages seen in larger, more mature pharmaceutical or biotech companies where ownership tends to be more diluted among institutional investors.

Related Party Transactions

• The filing details Dr. Chang's beneficial ownership, including shares held by the Chang 2006 Family Trust, JEC 2019 Trust, and RTC 2019 Trust, for which he is a co-trustee. These holdings represent related party interests.

Stakeholder Impact

• Shareholders: Dr. Chang's significant stake aligns his interests with other shareholders, potentially fostering confidence in the company's long-term direction.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this beneficial ownership report.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of beneficial ownership and does not contain new operational or financial information that would warrant a change in investment thesis. While Dr. Chang's substantial insider stake is a positive indicator of alignment, it does not provide a basis for a 'buy' or 'sell' recommendation without further fundamental analysis of Allogene Therapeutics' business performance and prospects.

Keywords

Allogene Therapeutics, ALLO, Beneficial Ownership, Schedule 13G, David D. Chang, Insider Ownership, Common Stock, Biotechnology, Pharmaceuticals, Trusts